Clinical Trial Update: Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring simultaneous integrated boost radiotherapy with nimotuzumab or chemotherapy for esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Neoplasms

Drugs mentioned

• Chemotherapy (chemotherapy)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Esophageal Neoplasms | Phase 2 | Status: UNKNOWN